ECSP045345A - Tratamiento de la gastroparesia - Google Patents
Tratamiento de la gastroparesiaInfo
- Publication number
- ECSP045345A ECSP045345A EC2004005345A ECSP045345A ECSP045345A EC SP045345 A ECSP045345 A EC SP045345A EC 2004005345 A EC2004005345 A EC 2004005345A EC SP045345 A ECSP045345 A EC SP045345A EC SP045345 A ECSP045345 A EC SP045345A
- Authority
- EC
- Ecuador
- Prior art keywords
- gastroparesia
- treatment
- glp
- patients
- compounds
- Prior art date
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 206010021518 Impaired gastric emptying Diseases 0.000 abstract 2
- 230000030136 gastric emptying Effects 0.000 abstract 2
- 208000001288 gastroparesis Diseases 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere al uso de compuestos de GLP-1 para tratar la gastroparesia. Los pacientes con gastroparesia experimentan generalmente un retraso en el vaciado gástrico. Los compuestos de GLP-1 se pueden usar para regular el vaciado gástrico en estos pacientes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37165002P | 2002-04-10 | 2002-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045345A true ECSP045345A (es) | 2006-04-19 |
Family
ID=29250714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004005345A ECSP045345A (es) | 2002-04-10 | 2004-10-08 | Tratamiento de la gastroparesia |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20050164925A1 (es) |
| EP (1) | EP1496924A4 (es) |
| JP (1) | JP2005530732A (es) |
| KR (1) | KR20040098063A (es) |
| CN (1) | CN1735423A (es) |
| AU (1) | AU2003220403A1 (es) |
| BR (1) | BR0308904A (es) |
| CA (1) | CA2480858A1 (es) |
| EA (1) | EA200401345A1 (es) |
| EC (1) | ECSP045345A (es) |
| HR (1) | HRP20040939A2 (es) |
| IL (1) | IL164266A0 (es) |
| MX (1) | MXPA04009929A (es) |
| NO (1) | NO20044815L (es) |
| NZ (1) | NZ535684A (es) |
| PL (1) | PL373658A1 (es) |
| WO (1) | WO2003087139A2 (es) |
| ZA (1) | ZA200408111B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
| US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| CA2539253A1 (en) * | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| JP2007537981A (ja) * | 2003-09-19 | 2007-12-27 | ノボ ノルディスク アクティーゼルスカブ | 新規の血漿タンパク質親和性タグ |
| ATE532459T1 (de) | 2004-08-18 | 2011-11-15 | Metacure Ltd | Überwachung, analyse und regulierung von essgewohnheiten |
| US9821158B2 (en) | 2005-02-17 | 2017-11-21 | Metacure Limited | Non-immediate effects of therapy |
| US9339190B2 (en) | 2005-02-17 | 2016-05-17 | Metacure Limited | Charger with data transfer capabilities |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| BRPI0608516A2 (pt) | 2005-03-18 | 2010-11-16 | Novo Nordisk As | análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto |
| US8265758B2 (en) * | 2005-03-24 | 2012-09-11 | Metacure Limited | Wireless leads for gastrointestinal tract applications |
| US8463404B2 (en) | 2005-03-24 | 2013-06-11 | Metacure Limited | Electrode assemblies, tools, and methods for gastric wall implantation |
| WO2006129321A2 (en) | 2005-06-02 | 2006-12-07 | Metacure N.V. | Gi lead implantation |
| US8442841B2 (en) * | 2005-10-20 | 2013-05-14 | Matacure N.V. | Patient selection method for assisting weight loss |
| US8295932B2 (en) | 2005-12-05 | 2012-10-23 | Metacure Limited | Ingestible capsule for appetite regulation |
| AU2012203915B9 (en) * | 2006-04-20 | 2014-10-09 | Amgen Inc. | GLP-1 compounds |
| MX2008013304A (es) * | 2006-04-20 | 2008-10-27 | Amgen Inc | Compuestos de peptido 1 tipo glucagon. |
| US8417329B2 (en) * | 2007-05-09 | 2013-04-09 | Metacure Ltd. | Analysis and regulation of food intake |
| US8423130B2 (en) * | 2008-05-09 | 2013-04-16 | Metacure Limited | Optimization of thresholds for eating detection |
| MX2011000847A (es) | 2008-08-06 | 2011-02-25 | Novo Nordisk Healthcare Ag | Proteinas conjugadas con eficacia prolongada in vivo. |
| MX2011007736A (es) | 2009-01-22 | 2011-09-06 | Novo Nordisk Healthcare Ag | Compuestos de hormona del crecimiento estables. |
| WO2011015649A1 (en) | 2009-08-06 | 2011-02-10 | Novo Nordisk Health Care Ag | Growth hormones with prolonged in-vivo efficacy |
| US8642548B2 (en) * | 2009-08-07 | 2014-02-04 | Mannkind Corporation | Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome |
| BR112012018162A2 (pt) | 2010-01-22 | 2017-10-03 | Novo Nordisk Healthcare Ag | Compostos de hormônio do crescimento estáveis |
| CN118767117A (zh) | 2010-01-22 | 2024-10-15 | 诺沃—诺迪斯克保健股份有限公司 | 体内功效延长的生长激素 |
| US8934975B2 (en) | 2010-02-01 | 2015-01-13 | Metacure Limited | Gastrointestinal electrical therapy |
| JP5827218B2 (ja) | 2010-04-30 | 2015-12-02 | 株式会社三和化学研究所 | 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| CN105120887A (zh) | 2013-04-05 | 2015-12-02 | 诺和诺德保健股份有限公司 | 生长激素化合物制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268343B1 (en) * | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| CA2283834A1 (en) * | 1997-03-31 | 1998-10-08 | James Arthur Hoffmann | Glucagon-like peptide-1 analogs |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
-
2003
- 2003-03-27 KR KR10-2004-7016025A patent/KR20040098063A/ko not_active Ceased
- 2003-03-27 CN CNA038080079A patent/CN1735423A/zh active Pending
- 2003-03-27 WO PCT/US2003/008457 patent/WO2003087139A2/en not_active Ceased
- 2003-03-27 EA EA200401345A patent/EA200401345A1/ru unknown
- 2003-03-27 US US10/508,762 patent/US20050164925A1/en not_active Abandoned
- 2003-03-27 MX MXPA04009929A patent/MXPA04009929A/es not_active Application Discontinuation
- 2003-03-27 EP EP03716707A patent/EP1496924A4/en not_active Withdrawn
- 2003-03-27 CA CA002480858A patent/CA2480858A1/en not_active Abandoned
- 2003-03-27 PL PL03373658A patent/PL373658A1/xx unknown
- 2003-03-27 JP JP2003584094A patent/JP2005530732A/ja active Pending
- 2003-03-27 AU AU2003220403A patent/AU2003220403A1/en not_active Abandoned
- 2003-03-27 BR BR0308904-5A patent/BR0308904A/pt not_active IP Right Cessation
- 2003-03-27 IL IL16426603A patent/IL164266A0/xx unknown
- 2003-03-27 HR HRP20040939 patent/HRP20040939A2/hr not_active Application Discontinuation
- 2003-03-27 NZ NZ535684A patent/NZ535684A/xx unknown
-
2004
- 2004-10-07 ZA ZA200408111A patent/ZA200408111B/xx unknown
- 2004-10-08 EC EC2004005345A patent/ECSP045345A/es unknown
- 2004-11-05 NO NO20044815A patent/NO20044815L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL164266A0 (en) | 2005-12-18 |
| CN1735423A (zh) | 2006-02-15 |
| MXPA04009929A (es) | 2006-03-10 |
| BR0308904A (pt) | 2005-05-03 |
| EP1496924A2 (en) | 2005-01-19 |
| WO2003087139A3 (en) | 2004-01-08 |
| JP2005530732A (ja) | 2005-10-13 |
| AU2003220403A1 (en) | 2003-10-27 |
| CA2480858A1 (en) | 2003-10-23 |
| US20050164925A1 (en) | 2005-07-28 |
| WO2003087139A2 (en) | 2003-10-23 |
| EA200401345A1 (ru) | 2005-08-25 |
| PL373658A1 (en) | 2005-09-05 |
| KR20040098063A (ko) | 2004-11-18 |
| EP1496924A4 (en) | 2007-05-30 |
| ZA200408111B (en) | 2005-10-07 |
| NO20044815L (no) | 2005-01-07 |
| HRP20040939A2 (en) | 2004-12-31 |
| NZ535684A (en) | 2006-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP045345A (es) | Tratamiento de la gastroparesia | |
| ATE461217T1 (de) | Glp-1-verbindungen | |
| MX2022001137A (es) | Compuestos agonistas de gipr. | |
| PA8534601A1 (es) | Activadores de glucocinasa del tipo isoindolin-1-ona | |
| PA8493701A1 (es) | Compuestos para tratar la obesidad | |
| ECSP055525A (es) | Inhibidores de cinasas de tirosina | |
| ECSP056210A (es) | Preparación y uso de derivados de alquilarilo para el tratamiento de la obesidad | |
| MX2008002293A (es) | Uso novedoso de compuestos peptidicos para tratar dolor muscular. | |
| EA200601747A1 (ru) | Три(цикло)замещённые амидные соединения | |
| ECSP034810A (es) | Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6 | |
| IS8485A (is) | Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki | |
| BRPI0511995A (pt) | uso de compostos peptìdicos para tratamento de dor em neuralgia trigeminal | |
| DE60026146D1 (de) | Verwendung von dapoxetin, a selektiver serotonin-aufnahme inhibitor mit schnellem wirkungseintritt, zur behandlung von sexueller dysfunction | |
| BRPI0409359A (pt) | análogos quiméricos de somatostatina-dopamina | |
| MX2007003032A (es) | Analogos de loxapina y metodos de uso de los mismos. | |
| UY27244A1 (es) | Uso del acido- (4´-trifluormetilfenil) - amida (z) -2- ciano-3- hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple | |
| CL2007002387A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor. | |
| HN2002000110A (es) | Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple. | |
| UY27203A1 (es) | Bencimidazoles útiles en el tratamiento de la disfunción sexual | |
| BR0209541A (pt) | Uso das imidazotriazinonas 2-fenil-substituìdas | |
| MXPA05001885A (es) | El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica. | |
| DK1532131T3 (da) | Motilid-forbindelser | |
| IL162154A0 (en) | Prostagandin composition for the treatment of erectile dysfunction | |
| NZ528164A (en) | Use of flumazenil to produce a medicament for the treatment of cocaine dependency | |
| SI1569634T1 (sl) | Uporaba PPAR-alfa agonista in metformina za zdravljenje obezitete |